Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - In response to press reports, say that it is conducting a review of strategic options, which may include soliciting offers for Tissue Regenix. Accordingly, the firm has contacted a limited number of potential counterparties to assess whether they could put forward a proposal ‘that would deliver greater value to Tissue Regenix’s shareholders than pursuing a standalone independent strategy’. Says it has not received any indicative non-binding proposals to date, and says there can be no certainty any offer will be made.

Current stock price: 61.67 pence

12-month change: up 10%

Copyright 2024 Alliance News Ltd. All Rights Reserved.